The fair value of requested stock should be $99.54
* Note: Prices are in Million (M) USD.
These criteria used Company’s Cash, EBITDA and Debt balance to determines its fair value:
Cash : $2,300 M
Debt : $1,960 M
EBITDA : $-463 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Healthcare
Industry: Biotechnology
Based on industry, 5 points assigned.
This criteria used Company’s Price To Earning (P/E) Ratio to determines its fair value:
Error: EPS must be a positive number.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Average Free Cash Flow: $-21 M
Average Revenue: $376 M
Free Cash Flow to Revenue : -6 %
Since Free Cash Flow (FCF) to Revenue percentage is negative, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $705 M
Revenue 4 Years Ago (2020-12-31): $729 M
Revenue Growth: -1%
Since Revenue Growth is between 0 - 5, 1 point assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $150 M
Share Count 5 Years Ago (2020-12-31): $140 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Error: Invalid Earnings Per Share value.Using default values for calculation.
Based on default values, 1 points assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Average ROE: -226%
Since Average ROE is negative, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $30
52-Week Low: $24
Threshold Price (15% Above 52-Week Low): $28
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $4,721 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the calculated score, we recommend do not exceed 2% exposure of Total Portfolio.
Value-Trade has assigned 10 points to above Ionis Pharmaceuticals Inc (IONS) stock.
Can't calculate fair value because earning per share is negative.Value-Trades has assined P/E value 20. Since current year earning per share is $-2.575.
The fair value of Ionis Pharmaceuticals Inc (IONS) stock should be (20 x $-2.575) = $-51.50
Join Discussion Group